SUGAR LAND, Texas, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today reported its financial results for the quarter ended June 30, 2025. Second Quarter 2025 Highlights: Generated revenue of $248.0 million, up $19.4 million, or 8.5% over the second quarter of 2024.Grew gr ...

FORT COLLINS, Colo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Woodward, Inc. (NASDAQ: WWD), a global leader in energy controls for aerospace and industrial markets, today announced key leadership changes aligned with the company’s continued focus on growth, innovation, and operational excellence. These changes will take effect on October 1, 2025. Shawn McLevige has been appointed President of Woodward’s Aerospace Segment. In this role, Shawn will report directly to Chip Blankenship, Chairman and CEO, as a member o ...

ATHENS, Greece, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (together with its subsidiaries, unless context otherwise dictates, “OET” or the “Company”) (NYSE: ECO, OSE: OET) today reported its unaudited condensed financial results for the second quarter and six-month period of 2025, which are attached to this press release. Financial performance of the Second Quarter Ended June 30, 2025 Revenues of $93.9 million in Q2 2025, compared to $112.0 million in Q2 2024.Profit of $26.9 million in Q2 ...

WILMINGTON, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares announced today the appointment of Jeffrey W. Lunsford to its board of directors. Lunsford has also been appointed to the board of directors of Live Oak Bank. “As a successful entrepreneur and financial technology expert, Jeff brings a deep level of technical expertise to our board,” said Live Oak Bancshares Chairman and CEO James S. (Chip) Mahan III. “His skill sets are an excellent match for Live Oak as we continue to redefine what it ...

Core Insights - Solid Biosciences is advancing its pipeline with three clinical-stage programs targeting neuromuscular and cardiac diseases, including SGT-003 for Duchenne Muscular Dystrophy, SGT-212 for Friedreich's Ataxia, and SGT-501 for Catecholaminergic Polymorphic Ventricular Tachycardia [2][4][9] Clinical Trials and Pipeline - The Phase 1/2 INSPIRE DUCHENNE trial has dosed 15 participants, with ongoing recruitment and no serious adverse events reported [1][3][5] - SGT-212 and SGT-501 are expected to initiate Phase 1b trials in Q4 2025, with SGT-212 being the first gene therapy for Friedreich's Ataxia utilizing a dual route of administration [1][4][6][9] - A randomized, double-blind, placebo-controlled trial for SGT-003 is planned outside the U.S. in Q4 2025 to support global regulatory authorizations [5] Financial Position - As of June 30, 2025, the company reported $268.1 million in cash and equivalents, providing a cash runway into H1 2027 [1][8] - Research and Development expenses for Q2 2025 were $32.4 million, up from $19.5 million in Q2 2024, primarily due to increased costs associated with SGT-003 [8][13] - The net loss for Q2 2025 was $39.5 million, compared to $25.1 million in Q2 2024, reflecting increased operational expenses [13][15] Strategic Partnerships and Technology - Solid has executed over 25 agreements for the use of its proprietary AAV-SLB101 capsid with academic labs and institutions [1][9] - The company is developing multiple next-generation capsid and promoter libraries, with the first cardiac capsid library selection expected in Q4 2025 [9] Market Position and Mission - Solid Biosciences is focused on improving the lives of patients with rare diseases, leveraging its expertise in genetic medicine to innovate therapies for conditions like Duchenne and Friedreich's Ataxia [2][11]

Financial Performance - Company reported record revenues of $23.1 million for the second quarter of 2025, an increase of 15% from $20.1 million in the first quarter of 2025 and 8% from $21.4 million in the second quarter of 2024 [2][8][14] - Gross profit for the second quarter of 2025 increased by 23% to $7 million, with a gross margin of 30.3%, up 7% sequentially from the first quarter of 2025 [2][9] - Net cash used in operating activities decreased by 54% to $2 million in the second quarter of 2025 compared to $4.3 million in the first quarter of 2025 [2][8] Cash Position - As of June 30, 2025, the company reported $15.7 million in cash, cash equivalents, and restricted cash, up from $12.3 million as of March 31, 2025 [2][10] - The company leverages its trades payable to finance operations, enhancing its cash position and lowering its cost of capital [10] Strategic Collaborations - Entered into a major collaboration with a $3 billion mixed-use smart city project in Miami, expected to supply over 500,000 units of its advanced smart home technologies [2][5] - Announced a sales and marketing collaboration with Parrot Uncle, a leading ceiling fan manufacturer, to jointly market SKYX's technologies [5] Product Development - Announced a surge in demand for its new patented all-in-one smart turbo heater and ceiling fan, targeting a multi-billion-dollar market [3][5] - The company has secured additional equity through preferred stock investments totaling approximately $15 million, indicating strong confidence from insiders [11] Market Expansion - Collaborating with major retailers like Home Depot and Wayfair to expand product offerings in both retail and professional segments [5][16] - The company is focused on growing its market penetration in the U.S. and Canada through its e-commerce platform of 60 websites [5][17] Safety and Standardization - The safety code standardization team is making progress with significant support from industry leaders, aiming for mandatory safety standards for its technologies [13] - The company believes its products can significantly reduce risks such as fires and electrocutions, potentially saving insurance companies billions annually [13]

LOUISVILLE, Ky., Aug. 12, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK) (the Company), a provider of personal safety, personal emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, today announced financial and operational results for the quarter ended June 30, 2025. Summary: Revenues were $2.9 million in the second quarter of 2025, an increase of 22% compared with the second quarter of 2024.Gross Profit in the second quarter of 202 ...

Core Insights - WEBTOON Entertainment reported strong second quarter results, with revenue and Adjusted EBITDA exceeding the top end of guidance ranges [1][3] - Total revenue for the second quarter was $348.3 million, reflecting an 8.5% increase year-over-year, while revenue growth on a constant currency basis was 5.5% [1][6] - The company experienced a net loss of $3.9 million, a significant improvement compared to a net loss of $76.6 million in the same quarter last year [1][6] Financial Performance - Adjusted EBITDA for the second quarter was $9.7 million, down from $20.4 million in the prior year, resulting in an Adjusted EBITDA margin of 2.8% compared to 6.3% [1][6] - The diluted loss per share was $0.03, compared to a diluted loss per share of $0.70 in the prior year [6] - Cash and cash equivalents stood at approximately $581.5 million, with no debt reported [1][6] Revenue Breakdown - Revenue growth was driven by all three revenue streams: Paid Content, Advertising, and IP Adaptations [3][6] - Paid Content revenue was $274.9 million, up 5.4% year-over-year, while Advertising revenue increased by 11.9% to $45.2 million [6][35] - IP Adaptations revenue saw a significant increase of 41.8%, reaching $28.1 million [6][35] Strategic Initiatives - The company announced a strategic collaboration with Disney to bring iconic comics from Marvel, Star Wars, and other franchises to its platform [4] - Recent updates to the English-language webcomic app aim to enhance user experience and engagement [3] Outlook - For the third quarter of 2025, the company expects revenue growth on a constant currency basis to be in the range of 9.4%-12.2%, translating to revenue between $380 million and $390 million [7]

Cepheus-1-36Q Rigetti’s Cepheus-1-36Q modular processor. Photo credit: Drew Bird Photography Cepheus-1-36Q processor assembly A single 9-qubit Rigetti chip being loaded into a mount for flip-chip bonding, the process used for assembling Rigetti’s Cepheus-1-36Q processor. Photo credit: Drew Bird Photography BERKELEY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its fi ...

Core Insights - Metagenomi, Inc. presented three abstracts at the American Society of Gene & Cell Therapy (ASGCT), showcasing early proof-of-concept data across multiple gene editing technologies [1] - The company reported a strong cash position of $205.0 million as of June 30, 2025, which is expected to support operations into 2027 [1][8] - The company is advancing its MGX-001 program for hemophilia A towards pre-IND and ex-U.S. regulatory meetings in 2025 [2] Financial Results - For the quarter ended June 30, 2025, research and development (R&D) expenses were $22.5 million, down from $28.3 million in the same period of 2024 [8] - General and administrative (G&A) expenses were $7.0 million for the quarter ended June 30, 2025, compared to $8.6 million for the same period in 2024 [8] - The net loss for the quarter was $19.9 million, compared to a net loss of $10.7 million in the same quarter of 2024 [15] Program Updates - The MGX-001 program for hemophilia A demonstrated durable FVIII activity levels through approximately 19 months, with mean FVIII activity of 75%, 8%, and 29% in three nonhuman primate subjects [7] - The company plans to submit an investigational new drug (IND) application in 2026 based on current data [7] - Key advancements in the gene editing platform were presented at ASGCT, including compact nucleases for extrahepatic gene editing and CRISPR-associated transposases (CAST) for large therapeutic gene integration [2][7] Corporate Developments - Laurence Reid, Ph.D., was appointed to the Board of Directors, bringing extensive experience in biotech [7] - A Research and Development Committee was established within the Board to provide insights on scientific and clinical strategies [7] Market Context - Hemophilia A is the most common X-linked inherited bleeding disorder, with an estimated prevalence of up to 26,500 patients in the U.S. and over 500,000 globally [9] - Metagenomi's gene editing toolbox has analyzed over 7.4 billion proteins, indicating its potential to target various genetic mutations across the human genome [10]